Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair dropped their FY2017 earnings per share (EPS) estimates for Hologic in a research note issued to investors on Thursday. William Blair analyst B. Weinstein now forecasts that the medical equipment provider will post earnings per share of $2.01 for the year, down from their prior estimate of $2.02.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same period in the prior year, the firm posted $0.51 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/09/hologic-inc-holx-to-post-fy2017-earnings-of-2-01-per-share-william-blair-forecasts.html.

HOLX has been the topic of a number of other reports. Jefferies Group LLC reiterated a “buy” rating and set a $49.00 price objective on shares of Hologic in a research note on Wednesday, June 28th. Barclays PLC reiterated an “overweight” rating and set a $53.00 price objective (up from $50.00) on shares of Hologic in a research note on Monday, July 17th. BidaskClub lowered Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Finally, Bank of America Corporation reiterated a “neutral” rating and set a $48.00 price objective (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $48.64.

Shares of Hologic (NASDAQ HOLX) traded down 1.322% on Monday, reaching $38.445. The company’s stock had a trading volume of 744,759 shares. Hologic has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market cap of $10.78 billion, a P/E ratio of 14.318 and a beta of 0.90. The firm’s 50 day moving average is $44.73 and its 200-day moving average is $42.94.

In other news, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter J. Valenti III sold 10,005 shares of the company’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the transaction, the insider now owns 20,994 shares of the company’s stock, valued at $911,979.36. The disclosure for this sale can be found here. Insiders sold a total of 60,627 shares of company stock valued at $2,632,911 over the last quarter. Company insiders own 0.79% of the company’s stock.

Several institutional investors have recently bought and sold shares of HOLX. TrimTabs Asset Management LLC boosted its position in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares during the last quarter. Advisor Partners LLC purchased a new position in Hologic during the first quarter worth about $201,000. Miles Capital Inc. purchased a new position in Hologic during the first quarter worth about $206,000. Beck Mack & Oliver LLC purchased a new position in Hologic during the second quarter worth about $209,000. Finally, Stratos Wealth Partners LTD. purchased a new position in Hologic during the first quarter worth about $210,000. Hedge funds and other institutional investors own 94.46% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.